Home » Newsletters » BioWorld Science

BioWorld Science

Jan. 22, 2009

View Archived Issues

Novel P2X7 receptor antagonists jointly discovered by AMRI and Schering-Plough researchers

Recent Roche patent reports new antipsychotic tachykinin NK3 receptor antagonists

Kyorin scientists describe new antibacterial mutilin derivatives

Novel mGluR5 receptor modulators with antipsychotic properties developed at GSK

Four Novartis medicines approved in a single day in Japan

Celldex licenses cholera and ETEC vaccine programs to Vaccine Technologies

Alexza initiates phase IIb clinical trial of Staccato loxapine in migraine

S*BIO grants worldwide exclusive license to Tragara to develop and commercialize SB-1317

Ablynx transfers in-house bone disorder R&D program with Procter & Gamble

3SBio files for approval in China for TPIAO label extension in ITP

Clinuvel reports positive phase III interim results for afamelanotide in EPP

European marketing authorization application for Flutiform delayed

Opexa provides update on pipeline developments

Xoma provides guidance update for 2008

Parkinson's disease drug Trerief obtains marketing approval in Japan

Recalbon/Bonoteo tablets approved in Japan for osteoporosis treatment

Bristol-Myers Squibb receives approval in Japan for Sprycel

Remitch approved in Japan for improvement of pruritus in hemodialysis patients

Merck & Co. divulge new gamma-secretase modulators for Alzheimer's disease

AVI reports positive results from phase I trial of AVI-4658 for DMD

Ecard approved in Japan for hypertension

RegeneRx presents update on clinical development of RGN-259 for nonhealing corneal ulcers

Aradigm reports positive results from phase II study of ILCH in bronchiectasis

Improved cyclin-dependent kinase inhibitor developed at Greenpharma

Vitamin effect on homocystine levels does not affect Abeta levels in stroke patients

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 24, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 24, 2025.
Researchers discover how glioblastoma tumors dodge chemotherapy
BioWorld MedTech
Researchers at the University of Sydney have uncovered a mechanism that may explain why glioblastoma returns after treatment, and the world-first discovery offers...
HIV research is close to a cure but far from ending the pandemic
BioWorld
Advances in antiretroviral therapy (ART) now allow people living with HIV to lead normal lives with undetectable and nontransmissible levels of the virus in their...
ADEL wins $1.04B Sanofi deal for tau-targeting Alzheimer’s drug
BioWorld
ADEL Inc. closed a year-end licensing deal worth up to $1.04 billion with Sanofi SA for ADEL-Y01, a specific tau-targeting Alzheimer’s disease drug candidate in a...